This change will take effect July 20, 2015
Overview and Clinical Utility:
Effective July 20, 2015, PathGroup will no longer perform testing for OVA1, a proprietary Aspira Labs assay used for the evaluation of ovarian masses. To avoid disruption in services, PathGroup will manage orders for OVA1 testing through a Third Party Phlebotomy Agreement.
Click Here to read more.